Laura G. Eichorn - Feb 22, 2022 Form 4 Insider Report for Imago BioSciences, Inc. (IMGO)

Role
Chief Operating Officer/Interim CFO
Signature
/s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn
Stock symbol
IMGO
Transactions as of
Feb 22, 2022
Transactions value $
-$152,653
Form type
4
Date filed
2/24/2022, 05:05 PM
Previous filing
Feb 15, 2022
Next filing
Jul 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGO Common Stock Options Exercise $20.2K +8K +3.85% $2.52* 216K Feb 22, 2022 Direct F1
transaction IMGO Common Stock Sale -$164K -7.6K -3.52% $21.57 208K Feb 22, 2022 Direct F1, F2
transaction IMGO Common Stock Sale -$8.86K -400 -0.19% $22.16 208K Feb 22, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -8K -7.28% $0.00 102K Feb 22, 2022 Common Stock 8K $2.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $21.03 to $21.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $22.07 to $22.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Chief Operating Officer/Interim CFO